Changes in serotonin·2 receptors have been demonstrated in brain autopsy material from patients with various neurodegenerative and affective disorders. It would be desirable to locate a ligand for the study of these receptors in vivo with positron emission tomogra phy (PET). Altanserin is a 4-benzoylpiperidine derivative with a high affinity and selectivity for S 2 receptors in vitro. Dynamic PET studies were carried out in nine nor mal volunteers with high-specific activity (376-1, 680 mCil J.Lmol) [ISFjaltanserin. Arterial blood samples were ob tained and the plasma time-activity curves were cor rected for the presence of labeled metabolites. Thirty minutes after injection, selective retention of the radioli gand was observed in cortical areas, while the cerebel lum, caudate, and thalamus had low radioactivity levels. Specific binding reached a plateau between 30 and 65 min postinjection at 1.8% of the injected dose/L of brain and Following the demonstration of dopamine recep tor labeling in the human brain in vivo with positron emission tomography (PET) (Wagner et aI., 1983), considerable efforts have been made to develop se lective high-affinity radioligands for other neurore ceptors. Adequate radioligands have been identified for imaging dopamine, opiate, benzodiazepine, and
then decreased, indicating the reversibility of the binding. The total/nonspecific binding ratio reached 2.6 for times between 50 and 70 min postinjection. The graphical anal ysis proposed by Logan et al. allowed us to estimate the binding potential (Bma)Ko). Pretreatment with ketanserin was given to three volunteers and brain activity remained uniformly low. An additional study in one volunteer showed that eSFjaltanserin can be displaced from the re ceptors by large doses of ketanserin. At the end of the study, unchanged altanserin was 57% of the total plasma activity. These results suggest that [ISFjaltanserin is se lective for S 2 receptors in vivo as it is in vitro. They indicate that eSFjaltanserin is suitable for imaging and quantifying S 2 receptors with PET in humans. Key Words: [ISFjAltanserin-Ketanserin-Positron emission tomog raphy-Serotonin-2 receptors.
cholinergic receptors with PET. New information is being obtained with PET regarding the role these neuroreceptors could play in several neuropsychi atric and neurological disorders (Wong et aI., 1986; Samson et aI., 1987; Frost et aI., 1989; Farde et aI., 1990; Frey et aI., 199 1; Mayberg et aI., 199 1) . Changes in serotonin receptors have been demon strated with PET in relation to age (Wong et aI., 1984; Blin et aI., 1990) and in post stroke depression (Mayberg et aI., 1988) . These in vivo binding stud ies also have great potential as a tool for assessing receptor occupancy (Farde et aI., 1988 ; Baron et aI., 1989) .
In vitro studies on brain autopsy material have revealed changes in S2 receptors in a variety of physiological states, such as sleep (Wesemann et al., 1983) and aging (Shih and Young, 1978; Sparks, 1989) , as well as in several neurological and psychi atric diseases, such as Alzheimer's disease (Cross et al., 1984 (Cross et al., , 1986 Crow et aI., 1984; Reynolds et aI., 1984) and affective and personality disorders (Stan ley and Mann, 1983; Mann et aI., 1986; Owen et aI., 1986; Curzon, 1988� Yates et a!., 1990 . Serotonin receptors are also involved in the hallucinogenic ac tions of some recreational drugs (Tileier et at., 1988). These data suffer from possible postmortem effects and limitations inherent to in vitro methods.
They suggest that in vivo studies of serotonin S2 receptors would be of great interest and would rep resent a significant advance in the understanding of these various conditions in which they are thought to be involved. Despite this evidence, few PET studies of serotonin receptors have been carried out so far, probably because a radioligand suitable for labeling them was lacking.
Attempts to label serotonin receptors in vivo were first carried out with l ll C ] ketanserin , [lIC] methylspiperone (Wong et aI., 1984) , [76Br] spiperone (Maziere et at., 1985) , ['Iqmethylketanserin (Frost et a!., 1987) , ['8Flfluo roethylaltanserin (Lemaire et aI., 1991 b) , and C 8 F]fluoroethylketanserin (Moerlein and Perlmut ter, 1991) . Besides their known poor selectivity for ketanserin, spiperone, and their analogues (Leysen and Gommeren, 1986; Moerlein and Perlmutter, 1991) , these tracers display low specific/nonspecific binding ratios and consequently are not ideal for human studies. Furthermore, the binding specificity of analogues such as [18F]fluoroethylaltanserin and [18F]fluoroethylketanserin has not been character· ized. Ratios of total· to-nonspecific binding ranging from t.7 to 2.7 have been observed with Nl-[methy/· 11C}2·bromine-LSO (C1C}MBL) (Wong et a!., 1987) . Only a limited number of human studies with this ligand have been reported so far and in vitro data suggest a possible secondary interaction with D2 receptors. In vivo binding of [lllFjsetoperone has recently been characterized (Blin et aI., 1988, (990) . Though this ligand appears to be suitable for label ing serotonin receptors in vivo, it is not selective for these receptors. As indicated in in vitro studies (Leysen and Gommeren, 1986) and by PET images, e8F]setoperone also binds to D2 receptors. A ligand with a better selectivity would be preferable (Frost, 1990) .
AItanserin is a 4-fluorobenzoylpiperidine deriva tive. It has a chemical structure close to that of ketanserin and setoperone. In vitro studies have in dicated that this ligand is 30-, 90-, 395-, and 697·fold more potent at serotonin receptors than at a I' HI' O2, and a2 receptors, respectively. It is also three J Cereb Blood Flo ... Mezah. Vv!. 15. Nv. 5. 1995 times more potent at S2 receptors than setoperone or ketanserin (Ley sen and Gommeren, 1986). Fur thermore, it has very low affinity for 5HT I A and 5HT lB receptors (Leysen, 1989) . Given these prop erties, we developed a route for the radio synthesis of (I B F]altanserin by nucleophilic fluorination of the corresponding nitro derivative (Lemaire et al., 199Ia) . Preliminary results obtained in rats have confirmed the potential of this radioligand for the in vivo mapping of serotonin Sz receptors (Lemaire et aI., 199Ia) . We report here the first studies with ll8F}altanserin and PET, and we describe the bind· ing characteristics of this new ligand in humans.
METHODS

Radiochemistry
Radiosynthesis of r 18Fjaltanserin was carried out by nucleophilic substitution of the nitro group with '8F -ac cording to a method published previollsly (Lemaire et aI., 199Ia) , but with several improvements in the purification steps to be reported elsewhere. The nitro precursor (ni· troaltanserin) has been synthesized in our laboratory. For each ' PET study, 15 to 40 mG of ['8Fjaltanserin was pro· duced. with an overall radiochemical yield of 6-16% at the end of synthesis. The synthesis time was about 120 min. The specific activity (SA) ranged from 550 to 1850 mCi/"",mol at the end of synthesis.
Subjects
Nine young normal volunteers, 22 to 30 years of age (mean, 25.4 ± "3.7 years), were recruited through adver· tisement. They had no history of neurological or psychi· atric disorders and they had never taken centrally active medication. They gave informed consent prior to the PET studies. The study protocol was approved by the local ethic committee.
Each subject had a baseline study with high-SA [18Pjaltanserin. Three of these subjects also had a block· ing study with ketanserin pretreatment. Cold ketanserin was given orally. They received 20 mg at 45 min and an additional 40 mg 30 min prior [18pjaltanserin, a dose that represents 0.81 ± 0.06 mg/kg. After oral administration, the bioavailability of ketanserin is of the order of 50% and the C",ax (peak plasma concentration) is reached at be tween 30 and 45 min. The plasma haH-life of ketanserin is more than 10 h (Persson et al., 199\) . Ketanserin is ap· proved for human use and commerciaiIy available in Bel gium (Sufrexal). The recommended initial dosage for hy· pertension treatment is 20 mg twice a day. r1lCjKetan· serin studies have indicated that this compound crosses the blood-brain barrier at a satisfactory 3.5% of the in· jected dose/L of brain (%lD/L) (Baron et aI., 1985) . A previous study (Blin et al.. 1990 ) has shown that chronic administration of 80 mg of ketanserin a day resulted in a significant reduction in the frontal cortex-to-cerebellum ratio with C8Pjsetoperone. The dose of 60 mg ketanserin was chosen as a potential blocking dose and two-step administration was decided on to lower the Cmax and therefore the risk of side effects. A displacement study was also carried out with 0.1 mg/kg i. v. ketanserin ad· ministered 57 min after [18Plaltanserin.
Datum acquisition
PET measurements were performed with a two-ring NeuroEcat PET scanner (EG&G; Ortec) (Hoffman et aI., 1983) operating in the high-resolution mode, yielding im ages with an in-plane spatial resolution of 8.6 mm and a slice thickness of 12.3 mm (at full width half-maximum).
Because only two direct planes can be acquired simul taneously with this tomographic system, it was necessary to select the planes of interest prior to dynamic PET stud ies. For that purpose, a thermolabile plastic face mask (Runtech, Liege, Belgium) was molded to the face of each subject. Limited x-ray computed tomography (CT) was used to identify two imaging planes parallel to the gla bella-inion line. The upper one passed through the cau date, the putamen, the thalamus, and various cortical re gions, while the lowest one passed through the cerebel lum. Once the planes of interest were identified, an alignment line was drawn on the face mask. This system ensured inter-and intraindividual, standardized, and re producible positioning (Frost et aI., 1988) .
A germanium-68 transmission scan was first obtained for photon attenuation correction. Seven to nine micro curies of [18F]altanserin were then intravenously injected in a volume of 17 ml, in I min, with an infusion pump. PET data acquisition was started immediately for 105 min with the following protocol: 4 x I min, 3 x 2 min, 5 x 5 min, and 5 x 10 min.
Plasma datum acquisition
During the study, blood samples were withdrawn via a catheter inserted previously into the brachial artery under local anesthesia. To characterize the plasma time-activity curves, a 2-ml arterial blood sample was obtained every 10 s during the first 3 min, then at 4, 5,7.5,10, 12.5, 15, 20,30,45,60,75 , and 90 min. Furthermore, eight arterial blood samples (from 2.5 to 10 ml) were collected for the determination of radioactive plasma metabolites.
HPLC analysis of plasma activity
The percentage of intact [18F]altanserin in the plasma was determined as follows. Each plasma sample (2 ml) was diluted in acetate buffer (5 . 10-2 M HAc, pH 4) to a final volume of 50 ml. The solution was slowly passed through a SepPak C-18 cartridge to extract the plasma activity. The column was then washed with 10 ml of water containing 0.1% triethylamine (TEA). The activity trapped on the SepPak was eluted with 2 ml of methanol. The radioactive solution was then eluted with 400 f.LI of H 2 0 with 0.1 % TEA to match the composition of the HPLC eluant (80% CH30HI19.9% H 2 0/O.1 % TEA). Dis solved authentic altanserin was added to the eluant. The efficiency of 18F plasma activity extraction by this pro cedure was found to be >92%. A C-18 f.LBondapak HPLC column was used, at a flow rate of 1 mllmin. Under these conditions, the retention time for unchanged [18F]altan serin was 8 min. A Amax Model 481 LC UV spectropho tometer (254 nm) from Waters and a Nal (TI) scintillation detector were installed in series for absorbance and ra dioactivity measurements.
Datum analysis
Attenuation-corrected images collected from the start to 20 min after injection were summed to enhance the anatomical details. These initial images are blood flow dependent and it is easier to identify the brain structures on these than on later images. Regions of interest (ROI; 3 x 3 pixels, or 0.7 cm 2 ) were then visually placed on both sides of the brain in the cerebellum (plane 1) and in the superior and inferior frontal cortex, the insular, superior temporal, temporoparietal, cingulate, and occipital cor tex, the caudate, and the thalamus. These regions were identified by comparison with neuroanatomical atlases (Aquilonius and Eckernas, 1980; Salamon and Huang, 1980) and the matching planes of the CT scan. The ROIs were then automatically transferred to each frame. The counts per pixel was transformed into %ID/L. Right and left values for each brain structure were averaged.
The plasma time-activity curves, also expressed as %ID/L, were corrected for the presence of labeled me tabolites.
An incorporation coefficient (lQ) was calculated as a way to normalize the data (Dewey et aI., 1990) :
where ROl(n is the concentration of tracer in a brain region at time T and C p the plasma activity. As a first attempt to model these studies, and to better characterize the binding properties of this ligand, we ap plied the graphi,cal analysis proposed by Logan et al. (1990) . Accordingly, when the binding of a ligand is re versible, there is a time tt after which a plot of
becomes linear. Neglecting the plasma volume, and as suming that the partition coefficient is the same for both regions, the ratio of the slope of the line in a region with receptors to that in a region without receptors is 1 + (BmaxIKD), with Bmax the concentration of receptors avail able for the ligand and KD the equilibrium dissociation constant of the ligand-receptor complex. Data are given with their standard deviations. The results presented in Table 1 are given with their coefficients of variation [(SDI mean) * 100].
RESULTS
For the baseline studies, the administered dose was 7.96 ± 0.96 mCi of [18F]altanserin at a SA of 852 ± 399 mCi/j..L mol (range, 470-1,680 mCi/j..L mol) at the time of injection, which corresponded to 0.068 ± 0.032 j..L g/kg altanserin. For the three block ing studies, the injection data are similar (7.90 ± 0.55 mCi, 700 ± 209 Ci/j..L mol, and 0.071 ± 0.021 j..L g/kg, respectively). Besides a transient dryness of the mouth, no side effect was experienced, despite the relatively high dose of ketanserin administered for the blocking or the displacement studies.
Chromatographic characterization of the plasma activity was carried out in eight of the nine baseline studies. Eight time points were examined. With the extraction method described above, the final recov ery of plasma activity was >92.2% regardless of the The parameters were calculated from the baseline studies at a high SA and during the studies with pretreatment with ketanserin. Data were calculated from the PET measurements carried out at between 50 and 70 min postinjection and averaged for the nine baseline studies or for the three studies with pretreatment with ketanserin (blocking studies). postinjection time. The retention time for un changed eSP]altanserin was ±8 min on the HPLC chromatogram, which showed the progressive growth of two peaks that corresponded to uniden tified substances more polar than [18P]altanserin. The kinetics of unmetabolized [18P]altanserin ex pressed as a fraction of the plasma activity is pre sented in Pig. 1. With time, the amount of un changed [18P]altanserin decreased according to a biexponential function (% unchanged [18P]altan serin = 0 .42e -0.0381 + 0.5ge -0.00051) . The coefficient of variation for the fraction of unchanged ligand was low (:;;;: 10%).
The regional distribution of the radioactivity in the two usual trans axial planes is shown in Pig. 2. These images from one volunteer are formed by summing the activity measured from 50 to 100 min postinjection and are representative of the images obtained in each of the baseline studies. e8P]Altan- serin was retained in all the cortical areas, where its concentration was rather uniform. In contrast, low radioactivity levels were observed in subcortical structures (thalamus, striatum, caudate), including the cerebellum. This distribution of the radioactiv ity is consistent with the known distribution of the serotonin receptors in the human brain (Schotte et aI., 1983) . After pretreatment with cold ketanserin, e8P]altanserin was no longer retained, and as a re sult, uniformly low levels of radioactivity were measured throughout the brain (Table 1) .
Pollowing the administration of [18P]altanserin, the radioactivity level was dynamically measured in various brain regions for up to 105 min after injec tion. The kinetics of the radioactivity, expressed as %ID/L, is shown in Pig. 3 for various representative brain regions. In cortical areas, as shown for the frontal, temporal, and parietal cortex, the activity slowly rose during 30 min and reached a peak at 3% ID/L. After a short plateau, the radioactive tracer concentration progressively decreased. In contrast, in the cerebellum, the peak of activity was earlier and the washout was much faster, which is indica tive of a lower degree of ligand retention in that region. Intermediate curves were observed for the thalamus and the caudate, but their shape was sim ilar to that of the cerebellum.
After ketanserin pretreatment, the kinetics of [18P]altanserin was the same in all brain regions and similar to that in the cerebellum during the baseline studies (Pig. 4).
The cerebellum is a region with very low levels of serotonin receptors (Schotte et aI., 1983; De Keyser et aI., 1988) . The activity in that region is assumed to be free and nonspecifically bound ligand (Wong et aI., 1987; Blin et aI., 1990) . Therefore, subtract- This CBFjaltanserin image rep resents the regional distribution of the radioactivity in the human brain from 50 to 100 min after intravenous administration of high-SA [1BFjaltanserin in a nor mal volunteer. These two trans axial planes are parallel to the glabella-inion line and are 32 mm apart. Five 10-min PET im ages were summed and smoothed to a final resolution of 11.6 mm in plane. The two planes are scaled to the same maximum. The radioactivity is retained in cortical areas, where it is rather homogeneously dis tributed. In contrast, low con centrations of 1BF are observed in the caudate, thalamus, and cerebellum.
ing the cerebellar activity from the activity in a re gion with receptors gives an estimation of the [ 18 P]altanserin specific binding. The kinetics of the radioligand concentration specifically bound to re ceptors is shown in Pig. 5 for the frontal cortex. This region is representative of what was observed in the other cortical regions both qualitatively and quantitatively. The net accumulation of [lsP]altan serin in receptor-rich areas increased up to 35-40 min postinjection and remained at a plateau for about 20 min. Thereafter, the specific binding slowly decreased. Specific binding was very low in the thalamus and the caudate.
The kinetics of the ratio of the activity measured in a receptor-rich region to that measured in the cerebellum (total/nonspecific binding) is shown in Fig. 6 . The ratio slowly increased up to 60 min postinjection and then leveled off for at least 20 min, indicating that a steady state occurred during that period of time.
The kinetics of [,sP]altanserin in the frontal cor tex during the displacement study is shown in Pig. 7, where it is compared to the kinetics of [ ' sP]altan serin in the same region during the baseline studies. Intravenous administration of a large dose of ket anserin resulted in a rapid displacement of [ ls P]altanserin from its binding sites.
Quantitative data from these studies are pre sented in Table 1 . They were obtained from various representative brain regions and were calculated from the radioactivity measured between 50 and 70 min postinjection, i.e., during the steady-state pe riod. The mean total binding was 3% ID/L in corti- cal regions during the baseline studies, indicating satisfactory penetration of the radioligand. There was little variation from one cortical region to an other. The total/nonspecific binding ratio was 2.6 in the cortical regions during the baseline studies and dropped to 1-1. 1 during the blocking studies, indi cating that complete blocking indeed occurred. The coefficient of variation for these data was <20%, sometimes <10%. The regional incorporation coef ficient ranged from 0.0088 in the cerebellum to 0.023 in the cortical regions during the baseline studies and was uniformly low across regions dur ing the blocking studies. As a first step toward kinetic modeling of these data, we applied Logan and co-workers' (1990) graphical analysis. A representative example of the results obtained with this approach is shown in Fig.  8A for two brain regions in one volunteer. This plot is typical of what was seen during the baseline stud ies in each brain region. In each case, for times of ing in the frontal cortex during the displacement study (n = 1) ( + ) is compared to that observed during the baseline stud ies (n = 9) (e). For the displacement study, 0.1 mg/kg ket anserin was administered as an intravenous bolus 57 min after high-SA [1BFjaltanserin. To allow the comparison, the two curves were normalized to their own maximum. > 15 min, the datum points (11) could be fitted to a straight line with a coefficient of correlation >0.98. The slope of a region with receptors was always greater than that of the cerebellum. The regional slopes are also presented in Table 1 . During the baseline studies, they ranged from 2.4 in cortical regions to 0.96 in the cerebellum. They dropped to 1 during the blocking studies. With these data, it is possible to calculate the binding potential (BP). The regional BP values are in good correspondence with the regional retention of [,sF]altanserin as well as with the known distribution of serotonin receptors in the human brain. Finally, as expected, Patlak plots (Patlak et aI. , 1983) of [,sF]altanserin data never resulted in a lin ear relationship as illustrated by the plot in Fig. 8B , which was obtained with the same data as in Fig.  8A .
DISCUSSION
The major finding of this study is that [lsF]altan serin is a suitable radioligand for imaging and quan tifying 5HT 2 receptors in vivo with PET. Its late distribution in the brain matches the known distri bution of 5HT 2 receptors in the human brain and it does not appear to bind to other receptors (i.e. , D2). Furthermore, acceptable total/nonspecific binding ratios are achieved at 1 h postinjection. Our PET studies are in line with our preliminary in vivo bind ing studies in rats, which have indicated the poten tial of [lsF]altanserin as a ligand for in vivo binding studies (Lemaire et aI. , 1991a) .
The first interesting property of [,sF]altanserin is its penetration into the brain. It crosses the blood brain barrier poth rapidly (peak concentration at 35 min postinjection) and in a sufficient amount (3% ID/L), resulting in satisfactory counting statistics despite the relatively low dose administered (8 mCi). The amount of ligand passing through the blood-brain barrier is in the same range as for other PET ligands, including [lsF]setoperone.
Second, for times of >30 min, the spatial distri bution of the regional brain concentrations of [lsF] altanserin is in agreement with the known dis tribution of 5HT2 receptors. The activity was uni formly retained in cortical areas, while it washed out from subcortical structures such as the striatum (rich in D2 and acetylcholine receptors), the thala mus (rich in (XI and opiate receptors), and the cer ebellum, which contains very low levels of S2 re ceptors (Schotte et aI. , 1983; Pazos et aI., 1987; De Keyser et aI. , 1988) . The intermediate uptake in the caudate (albeit closer to the cerebellum than the frontal cortex; Fig. 3 ) could reflect a relatively lower concentration of S2 receptors in that structure compared to the frontal cortex or a lower but dis tinct affinity for D2 sites. Thus, the PET images are indicative of the in vivo specificity of this ligand. The improved specificity of [ ,s F]altanserin has been established previously by in vitro biochemical stud ies (Leysen and Gommeren, 1986; Leysen, 1989) and by in vivo competition studies in rats with var ious specific ligands (Lemaire et aI. , 1991a) . Results obtained in rats may not be applicable to humans. Further methodological developments should in clude competition studies in nonhuman primates with competitors of well-defined specificity since there may be species differences between rats and primates for the distribution of specific receptors and for drug metabolism. The specificity of [ ls P]altanserin is its main advantage over eSP]se toperone. The latter ligand is used to label 5HT2 receptors with PET, but it also binds to D2 recep tors in vivo (Blin et aI., 1988 (Blin et aI., , 1990 . Our blocking studies indicate that the [lsP]altanserin binding sites are saturable and that the nonspecific binding (and therefore the partition coefficient) is uniform across all brain regions. They also confirm that it is valid to estimate the nonspecific binding in the cer ebellum.
The total/nonspecific binding ratio is an impor tant parameter in the evaluation of a radioligand, for it represents the signal/noise ratio. This should be as high as possible for maximum sensitivity in the detection of changes in the specific signal. In corti cal regions of young normal subjects, this ratio reaches an apparent steady state at between 50 and 80 min postinjection, at 2.6 ± 0.2 on average (range, 2.2 to 3). This is one of the best ratios observed in PET studies of serotonin receptors in the human brain. This is significantly higher than observed pre viously with other ligands, such as e IC]ketanserin [1.26 (Baron et aI., 1985) ], N-[IIC]methylspiperone [1.8 (Wong et aI., 1984)] , and N-[IIC]methylketan serin [2. 1 (Prost, 1990) ]. The mean total/nonspecific binding ratio obtained in the frontal cortex with [ISP]setoperone was 2.2 (Blin et aI., 1990) . The age range of the subjects in that study was much broader than in ours. An age effect has been ob served in serotonin receptor studies with N_[IIC] methylspiperone (Wong et aI., 1984) , IIC-MBL (Wong et aI., 1987) , and eSP]setoperone (Blin et aI., 1990) . In the latter study, the frontal cortex/ cerebellum ratio (F/C) decreased linearly with age according to a regression line described by the equation: F/C = 3.33 1 -0.028 x age. Correcting for that effect, the ratio would be 2.6 at 25 years old, a result similar to ours. This ratio of 2.6 is lower than expected from animal observations. In rat studies, ratios as high as 11 were observed in the frontal cortex (Lemaire et aI., 199 1a) . Similar dis crepancies between rat and human in vivo studies have been observed with other ligands (Prost, 1990) . The reason is not clear but several factors could account for these differences: The density of 5HT 2 receptors, measured in vitro with eH]ketan serin, was 30.9 fmol/mg tissue in the rat frontal cor tex (Leysen et aI., 1982) , while it was only 12.8 fmol/mg in the human cortex (Schotte et aI., 1983) ; true tissue ratios are certainly underestimated with PET because of the relatively low spatial resolution of the camera; and finally, differences in tissue lipid content between human and rat brain could result in higher nonspecific binding in human.
Separation of the chemical species that are la-J Cereb Blood Flow Me/ab. Vol. 15. No. 5. 1995 beled by ISp after systemic administration of [ ls P]altanserin was also an important point of this study. With an efficient and reliable method of plasma activity extraction and HPLC separation, the proportion of plasma activity corresponding to labeled metabolites increases with time. At least two metabolites more polar than [ ls P]altanserin are released in the plasma. Those metabolites should not cross the blood-brain barrier to any significant extent, a point supported by our previous rat stud ies, which have demonstrated the absence of la beled metabolites in rat brain for up to 4 h postin jection (Lemaire et aI., 1991a) .
Knowing the kinetics of unchanged [ ls P]altan serin in plasma, it is possible to apply kinetic mod eling techniques to our high-SA data to estimate the BP [BmaJK D (Mintun et aI., 1984) ] of eSP]altanserin in the human brain. It is best to apply a multi com part mental modeling approach with model parame ter . estimation by nonlinear least-squares fit to the experimental data. As a first step toward this more complex type of quantification, we analyzed out data with the graphical analysis developed by Lo gan et al. (1990) for ligands that reversibly bind to receptors. This method was designed for ligands that reach steady-state conditions during the time frame of the study, i.e., for ligands with rapid trans port and dissociation constants. The specific activ ity of the radioligand administered should be suffi ciently high so that the number of free binding sites is approximately equal to the B m ax . Where applica ble, this method is an easy and rapid way of esti mating the BP. The BP can be calculated from the ratio of the slope in a region with receptors to that in a region without receptors (here, the cerebellum), provided that the volume of distribution is the same for both regions and that the plasma volume is neg ligible. Inspection of the time-activity curves al ready suggested that eSP]aitanserin specific binding is reversible. As expected, for times of > 15 min utes, the Logan plots were linear in every region, which is an indication of the applicability of this method. In contrast, at early times «15 min), the plots were curvilinear, even in the cerebellum and during the blocking studies. This pattern is ex pected when there are more than two compart ments. Only for a two-compartmental model is the Logan plot linear at all times. A three-com partmental model was also required to describe ex plicitly [IIC]diprenorphine (Sadzot et ai., 199 1) , eSP]spiperone (Logan et aI., 1987) , or e IC]carfen tanil (Prost et aI., 1989) binding in brain regions devoid (or with very low levels) of receptors for these ligands. Why a third compartment is neces sary in these situations is unclear (Sadzot et aI., 199 1) . Given the relatively poor axial resolution and axial sampling of the tomograph used in this study, a small contribution of receptor binding in the oc cipital cortex during the baseline studies cannot be completely ruled out. This factor should, however, have been minimized by the strict anatomical selec tion of our planes of interest with a CT prior to each PET study, and should not contribute during the blocking studies anyway. BP estimates obtained by this graphical analysis are consistent with the dis tribution of serotonin receptors (Table 1) . The slopes of the Logan plots decreased with receptor saturation as indicated by the blocking studies. This suggests that the graphical method of Logan et ai. is sensitive to receptor occupancy. Further demon stration of this property should be obtained with studies carried out after the administration of vari ous nonsaturating doses of cold competitor. Pat lak's graphical analysis (Patlak et aI. , 1983) , which is applicable to ligands that are irreversibly trapped in tissue during the duration of the experiment, gave curvilinear plots with [18F)aitanserin (Fig. 8B ). This is another argument for the reversibility of the bind ing. Furthermore, on inspection of these Patlak plots (Fig. 8B) , it clearly appears that the relation did not become a horizontal asymptote before 50 min postinjection, i.e., that a steady state was not reached before that time. In contrast, the Logan plot of the same [ ls F)altanserin data becomes linear much earlier, at times > 15 min. Linearity of the Logan plot is also supposed to indicate that steady state conditions are achieved. This discrepancy has been considered and discussed by Logan et ai. (1990) . Under certain conditions, the ratio of terms in the intercept of their equation reaches the steady state value (i.e., linearity is reached) before the ra tio of terms in the intercept of the Patlak et ai. equa tion [ROI(t)/Cp)' Our preliminary model parameter estimations indicate that these conditions are met with eSF)altanserin as they were with N-e lC]meth ylcocaine.
A further advantage of eSF)altanserin is the high SA that can be achieved during radiosynthesis. The ligand was therefore administered in low amounts (0.07 f.Lg/kg). If the 5HT2 receptor density is 12.9 fmol/g tissue in the frontal cortex (Schotte et aI. , 1983) , the receptor occupancy during our studies is in the range of 2-3% at the peak. No pharmacolog ical effect was observed or experienced after ket anserim administration. Serotonin antagonists are not expected to trigger psychotropic side effects (Awouters et aI., 1988; Leysen and Pauwels, 1990) . Not surprisingly, even after the large doses of ket anserin administered during the blocking or dis placement studies, no serious side effect was re-ported. This is clearly an advantage if full quantifi cation is desired, because a low-SA study (i.e. , with a higher mass of ligand) is required, in addition to a high-SA study, to estimate separately Bma x and Ko (Farde et aI. , 1990; Sadzot et aI. , 199 1) . More data should be available, though, on the inocuity of al tanserin before carrying out experiments with this ligand at a low SA.
